Paper Details

  1. Home
  2. Paper Details

Efficacy of histamine H1 receptor antagonists azelastine and fexofenadine against cutaneous Leishmania major infection.

Author: MelbyPeter C, OsorioE Yaneth, PenicheAlex G, TraviBruno L

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

Cutaneous leishmaniasis is a parasitic skin infection. Current treatments are often difficult to administer and can be ineffective. This study investigated the effects of histamine 1-receptor antagonists (H1RAs), anti-allergy medications, on leishmaniasis in mice. Azelastine and fexofenadine, two types of H1RAs, were found to be effective at reducing the size of lesions and killing the parasite in the skin and lymph nodes. H1RAs may be promising new treatments for cutaneous leishmaniasis.
Paper Details　
Original Abstract of the Article :
Current drug therapies for cutaneous leishmaniasis are often difficult to administer and treatment failure is an increasingly common occurrence. The efficacy of anti-leishmanial therapy relies on a combination of anti-parasite activity of drugs and the patient's immune response. Previous studies hav...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449455/

データ提供：米国国立医学図書館（NLM）

Histamine H1 Receptor Antagonists for Cutaneous Leishmaniasis: A New Oasis in a Desert of Challenges

The study explores the therapeutic potential of histamine H1 receptor antagonists (H1RAs) in treating cutaneous leishmaniasis, a parasitic disease that causes skin lesions and often poses significant challenges for treatment. The researchers investigated the efficacy of azelastine and fexofenadine, two commonly used H1RAs, against Leishmania major infection in both in vitro and in vivo models.

A Promising Path: H1RAs as a Potential Treatment

The study demonstrated a significant anti-leishmanial activity of azelastine and fexofenadine in both in vitro and in vivo models. These findings suggest that H1RAs might offer a promising new approach to treating cutaneous leishmaniasis, particularly when current treatments are difficult to administer or ineffective. Imagine discovering a new oasis in a desert landscape, offering a refreshing respite from the challenges of traditional treatments; this study explores the potential of H1RAs as a new source of hope for patients with cutaneous leishmaniasis.

Exploring New Therapies: A Quest for Solutions

This study offers a compelling case for further research into the potential of H1RAs in treating cutaneous leishmaniasis. It highlights the importance of exploring new therapeutic avenues to address the challenges of this parasitic disease. Like a desert traveler seeking a reliable source of water, the search for effective treatments for cutaneous leishmaniasis continues, and this study offers a promising lead.

Dr. Camel's Conclusion

This study sheds light on the potential of histamine H1 receptor antagonists (H1RAs) as a novel therapeutic approach for cutaneous leishmaniasis. The encouraging results warrant further investigation into the efficacy and safety of H1RAs in treating this challenging parasitic disease. Just as a desert explorer discovers a new source of water, this research offers hope for a more effective and accessible treatment for patients struggling with cutaneous leishmaniasis.
Date :
  1. Date Completed 2020-09-10
  2. Date Revised 2020-09-10
Further Info :

Pubmed ID

32776923

DOI: Digital Object Identifier

PMC7449455

Related Literature

Article Analysis
・Side Effects of fexofenadine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.